Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Oliver R. Thiel"'
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
Autor:
Liang Zhang, Daniel J. Griffin, Matthew G. Beaver, Laura E. Blue, Christopher J. Borths, Derek B. Brown, Seb Caille, Ying Chen, Alan H. Cherney, Brian M. Cochran, John T. Colyer, Michael T. Corbett, Tiffany L. Correll, Richard D. Crockett, Xi-Jie Dai, Peter K. Dornan, Robert P. Farrell, Simon J. Hedley, Hsiao-Wu Hsieh, Liang Huang, Seth Huggins, Min Liu, Michael A. Lovette, Kyle Quasdorf, William Powazinik, Jonathan Reifman, Jo Anna Robinson, Rahul P. Sangodkar, Sonika Sharma, Srividya Sharvan Kumar, Austin G. Smith, Gabrielle St-Pierre, Jason S. Tedrow, Oliver R. Thiel, Jonathan V. Truong, Shawn D. Walker, Carolyn S. Wei, Ashraf Wilsily, Yong Xie, Ning Yang, Andrew T. Parsons
Publikováno v:
Organic Process Research & Development. 26:3115-3125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::972bf6936d6ce0633f15e7dda136b897
https://doi.org/10.1021/acs.oprd.2c00249
https://doi.org/10.1021/acs.oprd.2c00249
Autor:
Xi-Jie Dai, Paul Krolikowski, James I. Murray, Carolyn S. Wei, Peter K. Dornan, Andreas R. Rötheli, Seb Caille, Oliver R. Thiel, Austin G. Smith, Andrew T. Parsons
Publikováno v:
The Journal of Organic Chemistry. 87:8437-8444
An organocatalyzed, formal (3+3) cycloaddition reaction is described for the practical synthesis of substituted pyridines. Starting from readily available enamines and enal/ynal/enone substrates, the protocol affords tri- or tetrasubstituted pyridine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e1271b206782db094b974c62bc65c6e
https://doi.org/10.1021/acs.joc.2c00576
https://doi.org/10.1021/acs.joc.2c00576
Autor:
Elçin Içten, Seb Caille, Gabrielle St-Pierre, Oliver R. Thiel, Sharon E. Michalak, Matthew G. Beaver
Publikováno v:
Israel Journal of Chemistry. 61:369-379
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::315c4647fa0e1c758d1d1c73e6107d03
https://doi.org/10.1002/ijch.202100006
https://doi.org/10.1002/ijch.202100006
Autor:
Alan M. Allgeier, Krishnakumar Ranganathan, Seb Caille, Sheng Cui, Andrew Cosbie, Jacqueline C. S. Woo, Steven M. Mennen, Oliver R. Thiel, Shawn D. Walker, Justin T. Tvetan, Seth Huggins, Neil F. Langille, Richard D. Crockett, Xianqing Shi, Karl B. Hansen, Charles Bernard, Kyle Quasdorf, Fang Wang, Alexander Muci, Bradley P Morgan, Philipp Roosen, Steven Wu, Henry Morrison, Tiffany L. Correll, Margaret M. Faul, Karthik Nagapudi
Publikováno v:
Organic Process Research & Development. 23:1558-1567
The development of a factory process to manufacture the novel cardiac myosin activator omecamtiv mecarbil (1) is described. Omecamtiv mecarbil is prepared via the convergent synthesis and coupling ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6f4fdc9437c03c0ff4b2e4caac4c921
https://doi.org/10.1021/acs.oprd.9b00200
https://doi.org/10.1021/acs.oprd.9b00200
Autor:
Andreas R. Rötheli, Oliver R. Thiel, Austin G. Smith, Jason S. Tedrow, Seb Caille, Matthew G. Beaver, Robert P. Farrell
Publikováno v:
Synlett.
The last decade of small-molecule process development has witnessed a trend of increasing molecular complexity for clinical candidates. The continued advance of novel catalytic methods and subsequent translation to efficient and scalable processes ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9f3c70b685f8540bfc9a1d59b3a0102
https://doi.org/10.1055/s-0040-1706869
https://doi.org/10.1055/s-0040-1706869
Autor:
Simon J. Hedley, Michele Kubryk, Zhenxin Lin, Oliver R. Thiel, Matthew S. Potter-Racine, David Bauer, Andrew T. Parsons
Publikováno v:
Organic Process Research & Development. 22:898-902
An improved API step for the formation of an aminopyrimidine-based kinase inhibitor is described. The presence of a reactive acrylamide functional group presented a considerable challenge during scale-up, resulting in side-product formation and low i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4104503cedd7c403daed4399121a7b5c
https://doi.org/10.1021/acs.oprd.8b00080
https://doi.org/10.1021/acs.oprd.8b00080
Publikováno v:
Chemical Science
A new method for Co/NHPI-catalyzed aerobic C–H oxygenation shows excellent tolerance of electronically diverse heterocycles.
A simple cobalt(ii)/N-hydroxyphthalimide catalyst system has been identified for selective conversion of benzylic meth
A simple cobalt(ii)/N-hydroxyphthalimide catalyst system has been identified for selective conversion of benzylic meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad82ba77b2ae5d337c7482adfcf68d3e
https://doi.org/10.1039/c6sc03831j
https://doi.org/10.1039/c6sc03831j
Autor:
Mirna Mujacic, John B. Jordan, Pranhitha Reddy, Aleksander Swietlow, Vivian S. W. Li, Tisha San Miguel, Paul Kodama, Anne-Marie C Rousseau, Seb Caille, E. Allen Sickmier, Michael J. Frohn, Dhanashri Bagal, Steve Osgood, Christopher H. Fotsch, Ki Won Kim, John D. McCarter, Mike Achmatowicz, Oliver R. Thiel, Alex Pickrell, Yong-Jae Kim, John G. Allen
Publikováno v:
ACS Chemical Biology. 11:2734-2743
The efficacy of therapeutic antibodies that induce antibody-dependent cellular cytotoxicity can be improved by reduced fucosylation. Consequently, fucosylation is a critical product attribute of monoclonal antibodies produced as protein therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7973a8b4af60302b46b36632b02c9cd0
https://doi.org/10.1021/acschembio.6b00460
https://doi.org/10.1021/acschembio.6b00460
Publikováno v:
Organic & Biomolecular Chemistry. 14:9549-9553
An ideal drug should be highly effective, non-toxic and be delivered by a convenient and painless single dose. We are still far from such optimal treatment but peptides, with their high target selectivity and low toxicity profiles, provide a very att
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15599b68a1798f462651c740963fffa0
https://doi.org/10.1039/c6ob01833e
https://doi.org/10.1039/c6ob01833e
Autor:
Carl Davis, Qiong Wu, Oliver R. Thiel, Robert R. Milburn, Jodi L. Liu, Y.-H. Kiang, Eric A. Bercot, Christopher J. Borths, Robert E. Saw, Dawn E. Cohen, Richard J. Staples
Publikováno v:
Organic Process Research & Development. 19:1849-1858
AMG 579 (1) is a potent and selective phosphodiesterase 10 (PDE10A) inhibitor selected for clinical development for the treatment of schizophrenia. Extensive polymorph and salt screening identified two free-base anhydrous polymorphs (Form 1 and Form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9b06eaa6b031c67cb79c311ae7587d8
https://doi.org/10.1021/acs.oprd.5b00031
https://doi.org/10.1021/acs.oprd.5b00031